echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > mRNA respiratory syncytial virus vaccine launches global clinical trial

    mRNA respiratory syncytial virus vaccine launches global clinical trial

    • Last Update: 2021-12-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Moderna announced that the Phase 2/3 clinical trial of the candidate vaccine mRNA-1345 has completed the first patient administration for the prevention of respiratory syncytial virus (RSV) infection


    RSV is a common respiratory virus that generally causes cold-like symptoms.


    mRNA-1345 is an mRNA vaccine encoding the F glycoprotein before stable fusion of the virus.


    In a phase 1 clinical trial conducted in young adults, one month after subjects received a single dose of vaccine (100 μg), the geometric mean titers of neutralizing antibodies against RSV-A or RAV-B increased by 21 times and respectively compared with baseline.


    In addition, Moderna's respiratory virus research and development project also includes the development of mRNA vaccines against other viruses such as seasonal influenza


    Reference materials:

    [1] Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.